Iron Deficiency News and Research RSS Feed - Iron Deficiency News and Research

UCSF researchers discover memory-boosting molecule in mice

UCSF researchers discover memory-boosting molecule in mice

Memory improved in mice injected with a small, drug-like molecule discovered by UCSF San Francisco researchers studying how cells respond to biological stress. [More]
New app for iPhone helps detect toxins, proteins, bacteria and viruses

New app for iPhone helps detect toxins, proteins, bacteria and viruses

Researchers and physicians in the field could soon run on-the-spot tests for environmental toxins, medical diagnostics, food safety and more with their smartphones. [More]
Research finds number of links between dental health and overall health

Research finds number of links between dental health and overall health

If the eyes are the windows to your soul, then your mouth is the gateway to your overall health. Research has found a surprising number of links between the state of your dental health and your overall health. [More]
Intermediate anti-tTG levels affects birth outcomes, new study reveals

Intermediate anti-tTG levels affects birth outcomes, new study reveals

Pregnant women with mid to high levels of antibodies common in patients with celiac disease are at risk for having babies with reduced fetal weight and birth weight, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association. [More]

FDA accepts AMAG’s Feraheme sNDA for review

AMAG Pharmaceuticals, Inc. today announced that the United States Food and Drug Administration (FDA) has accepted for review the company's supplemental new drug application (sNDA) for Feraheme (ferumoxytol) Injection for Intravenous (IV) use, which was submitted to the FDA in December 2012. [More]
Zinc protoporphyrin a marker for iron deficiency in low-income children

Zinc protoporphyrin a marker for iron deficiency in low-income children

Researchers say that zinc protoporphyrin could be a useful measure for screening infants from low-income families for iron deficiency, as well as for monitoring response to therapy, especially among children with anemia. [More]
Keryx prices underwritten public offering of common stock

Keryx prices underwritten public offering of common stock

Keryx Biopharmaceuticals, Inc. today announced the pricing of its previously announced underwritten public offering of common stock consisting of 8,234,000 shares at $8.49 per share. [More]

AMAG seeks FDA sNDA approval for Feraheme Injection

AMAG Pharmaceuticals, Inc. today announced that it has submitted a supplemental new drug application (sNDA) to the United States Food and Drug Administration (FDA) for Feraheme (ferumoxytol) Injection for Intravenous (IV) use. [More]
Two cups of milk per day is enough to maintain adequate vitamin D levels for children

Two cups of milk per day is enough to maintain adequate vitamin D levels for children

New research has answered one of the most common questions parents ask their doctors: How much milk should I be giving my children? The answer is two cups per day. [More]

AMAG presents new data from two ferumoxytol phase III trials on IDA at ASH annual meeting

AMAG Pharmaceuticals, Inc. today announced that new data from two pivotal phase III clinical trials were presented at the American Society of Hematology's (ASH) annual meeting in Atlanta, Georgia. [More]
Beth Israel Deaconess Medical Center introduces CeliacNow website

Beth Israel Deaconess Medical Center introduces CeliacNow website

It's estimated that one in 100 people in the United States are living with celiac disease, but there are only a handful of celiac centers throughout the country. In response to a growing need for educational materials, clinicians at Beth Israel Deaconess Medical Center's Celiac Center have launched CeliacNow, a nutritional management website designed to maximize the health and wellbeing of people living with celiac disease and other gluten-related disorders. [More]
NOXXON commences NOX-H94 Phase IIa trial to treat anemia of chronic disease

NOXXON commences NOX-H94 Phase IIa trial to treat anemia of chronic disease

NOXXON Pharma today announced the treatment of the first patients in a Phase IIa clinical trial of its anti-hepcidin Spiegelmer NOX-H94 to treat anemia associated with chronic disease. [More]
UI researchers develop neonatal piglet model to study micronutrient deficiencies

UI researchers develop neonatal piglet model to study micronutrient deficiencies

University of Illinois researchers have developed a model that uses neonatal piglets for studying infant brain development and its effect on learning and memory. To determine if the model is nutrient-sensitive, they have done some research on the effects of iron-deficient diets. [More]
Atpif1 gene regulates hemoglobin synthesis during red blood cell formation

Atpif1 gene regulates hemoglobin synthesis during red blood cell formation

Researchers at Brigham and Women's Hospital (BWH) have discovered a new gene that regulates hemoglobin synthesis during red blood cell formation. The findings advance the biomedical community's understanding and treatment of human anemias and mitochondrial disorders. [More]
Sabin initiates Part II of Na-GST-1 vaccine Phase I hookworm trial

Sabin initiates Part II of Na-GST-1 vaccine Phase I hookworm trial

The Sabin Vaccine Institute (Sabin) today announced the start of Part II of its Phase I clinical trial of the Na-GST-1 vaccine candidate, marking another major milestone in the progress toward developing a human hookworm vaccine. [More]
Takeda, Affymax announce data from OMONTYS Phase 3 studies on anemia due to CKD

Takeda, Affymax announce data from OMONTYS Phase 3 studies on anemia due to CKD

Affymax, Inc. and Takeda Pharmaceuticals U.S.A., Inc. (TPUSA) today announced the presentation of post-hoc sub-group analyses of the EMERALD Phase 3 studies that evaluated OMONTYS (peginesatide) Injection, an erythropoiesis-stimulating agent (ESA), for the treatment of anemia due to chronic kidney disease (CKD) in adult dialysis patients. [More]

Anemia now confirmed as risk factor for illness and even death following cardiac surgery

Anemia is now confirmed as a risk factor for illness and even death following cardiac surgery, according to a study published in the October 2012 issue of The Annals of Thoracic Surgery. [More]

AMAG receives Swiss marketing authorization for ferumoxytol to treat iron deficiency anemia

AMAG Pharmaceuticals, Inc. today announced that the Swiss Agency for Therapeutic Products (Swissmedic) has granted marketing authorization in Switzerland for ferumoxytol, an intravenous (IV) iron therapy to treat iron deficiency anemia (IDA) in adult patients with chronic kidney disease. [More]

Prenatal alcohol exposure effects last well into childhood

Women who heavily expose their unborn child to alcohol risk restricting their child’s growth until the age of 9 years, researchers say. [More]
Study tracks effects of heavy PAE on growth and body composition throughout childhood

Study tracks effects of heavy PAE on growth and body composition throughout childhood

Although studies of alcohol's effects on fetal growth have consistently demonstrated deficits that persist through infancy, the data on long-term postnatal growth from human studies have been inconsistent. A new study of the effects of heavy prenatal alcohol exposure (PAE) on growth and body composition throughout childhood has found growth restrictions that persist through to nine years of age, as well as a delay in weight gain during infancy, both of which were exacerbated by iron deficiency. [More]